Concord Biotech sets Sept 25 start for postal ballot on bonus issue
- Remote e-voting for Concord Biotech's bonus issue starts September 25, 2026
- Shareholder cut-off date for voting eligibility is September 18, 2026
- Proposed 1:1 bonus issue requires capitalising ₹10.46 crore from securities premium
- Authorised share capital increase to ₹22 crore included in postal ballot resolutions
*this image is generated using AI for illustrative purposes only.
Concord Biotech Limited has commenced the shareholder approval process for its proposed 1:1 bonus issue and increase in authorised share capital to ₹22 crore. Remote e-voting for the resolutions begins on September 25, 2026, and concludes on October 24, 2026.
The company notified stock exchanges on September 24, 2026, regarding the dispatch of the Postal Ballot Notice dated September 23, 2026. The notice seeks member approval for two ordinary resolutions: increasing authorised capital and issuing bonus shares by capitalising the securities premium account.
Bonus Issue Details
The Board approved the issuance of bonus equity shares in the proportion of 1:1, meaning one fully paid-up equity share of ₹1 each for every one existing equity share held by shareholders as on the record date. This issuance will be executed by capitalising the share premium account.
| Particulars | Details |
|---|---|
| Type of securities | Equity shares of ₹1 each |
| Bonus ratio | 1:1 |
| Total number of shares | 10,46,16,204 |
| Source of funds | Share premium account |
| Pre-bonus paid-up capital | ₹10,46,16,204 |
| Post-bonus paid-up capital | ₹20,92,32,408 |
| Estimated credit date | By November 22, 2026 |
Authorised Capital Increase
Concurrently, the Board approved an increase in the Company’s authorised share capital from ₹11 crore to ₹22 crore. This involves the creation of an additional 11,00,00,000 equity shares of ₹1 each, ranking pari passu with existing shares. Consequently, Clause V of the Memorandum of Association will be amended to reflect the new authorised capital structure.
Voting Timeline and Eligibility
Shareholders whose names appear in the Register of Members as on September 18, 2026, are eligible to vote. The remote e-voting period is scheduled as follows:
| Event | Date |
|---|---|
| Cut-off date for eligibility | September 18, 2026 |
| Commencement of remote e-voting | September 25, 2026 |
| End of remote e-voting | October 24, 2026 |
Voting rights are proportional to the amount paid up on the total number of equity shares held as on the cut-off date. Institutional members must send board resolutions authorising their representatives to vote to the scrutinizer, Mr. Ashish Shah of M/s. Ashish Shah & Associates.
Regulatory Compliance
The intimation was issued pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company notified both the National Stock Exchange of India Limited and BSE Limited regarding the scheduled meeting and its outcomes.
Paritosh Trivedi, Company Secretary & Compliance Officer, signed the disclosure on September 23, 2026.
Historical Stock Returns for Concord Biotech
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.97% | -5.55% | -11.56% | +23.94% | -15.81% | +36.38% |
How might the doubling of paid-up capital through the 1:1 bonus issue impact Concord Biotech's stock liquidity and trading volume on the NSE and BSE?
What strategic growth initiatives or capital expenditure plans is Concord Biotech likely to fund using the newly increased ₹22 crore authorised share capital?
Could the capitalisation of the securities premium account for the bonus issue affect the company's future dividend distribution capacity or balance sheet flexibility?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
